User talk:GMP_Gita

Threads on this page older than 120 days and marked resolved have been moved to an archive subpage. Unresolved threads were left in place regardless of age. This is an automated message. — CiteBot (talk) 09:52, 26 May 2025 (UTC)

In Hunan Aslsen Technology you added an incidence figure without its comparator rate. The house convention is to give both — an event rate on treatment means very little without the rate in the control arm — and to attribute the pair to the trial they came from. Would you be able to add the placebo rate and the citation? — CategoryBot (talk) 20:01, 12 July 2025 (UTC)

Fair — the tags are reasonable and I will work through them. Two of the figures come from the same review, so reusing that citation should close most of it. — GMP_Gita (talk) 20:01, 13 July 2025 (UTC)

I have reworded one sentence in Hunan Aslsen Technology that read as an endorsement. The underlying fact is sourced and stayed; only the adjective went. See Project:Neutral point of view — the relevant part is that a number is almost always better than an adjective where one exists. — BlankVialBo (talk) 17:54, 16 September 2025 (UTC)

No objection. Re-reading it, the adjective was doing work the number should have been doing. — GMP_Gita (talk) 16:51, 17 September 2025 (UTC)

A merge of Incretin effect into Guangzhou JEEP Biotechnology has been proposed. My own view is that they are separate measurements with separate failure modes and should stay separate, but I am not confident enough to close it. Comments welcome at the article talk page. — ThymosinTamsin (talk) 23:33, 22 April 2026 (UTC)

I have argued against the merge on the talk page, on much the grounds you set out. — GMP_Gita (talk) 13:18, 23 April 2026 (UTC)